EU Approval Expands the Indication
Merz Aesthetics announced on February 1, 2024 that Radiesse received EU approval for use in the neck area. This expands the product's clinical positioning and gives the market another concrete example of how CaHA-based fillers continue to evolve.
Because Radiesse is already a widely recognized product, the new indication has significance beyond a single brand announcement.
The Material Platform Behind Radiesse
Radiesse is based on calcium hydroxyapatite microspheres suspended in a gel carrier. The microspheres provide structural support while also being associated with longer-term collagen-related tissue response, which is why the category remains important in regenerative aesthetics.
That material design helps explain why regulatory progress around Radiesse is also relevant to broader CaHA material development.
Why the Approval Matters
As mature international products continue to expand their approved uses, developers and suppliers gain a clearer reference point for compliance strategy, indication planning, and material positioning in related categories.
For teams following hydroxyapatite microspheres, the approval is a useful industry signal that category development is still moving forward.